INCY, Roche ink non-exclusive clinical collaboration to test IDO1 inhibitor (INCB24360) with PD-L1 inhibitor (MPDL3280A): http://finance.yahoo.com/news/incyte-announces-clinical-trial-agreement-123000170.html Incyte will be responsible for conducting the study and the results will be used to determine whether further clinical development of this combination is warranted. Further details of the agreement were not disclosed.Similar to INCY’s non-exclusive clinical collaborations with AZN (#msg-101978540) and BMY (#msg-102526464).